The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Using engineered CALR-mutant human HSCs to improve our understanding of MPNs
Johannes Foßelteder
• 17 May 2022
Johannes Foßelteder, Medical University of Graz, Graz, Austria, outlines the limitations of current models for calreticulin (CALR)-mutant hematopoietic stem cells (HSCs), and describes a new promising pre-clinical CRISPR knock-in model that models human CALR-mutated MPNs more faithfully and can be used to better understand the pathogenesis of MPNs or to screen for novel therapeutics. This interview took place virtually.
